Form 6-K NOVO NORDISK A S For: May 23
- S&P 500 closes the book on its biggest first-half plunge since 1970
- Micron (MU) Shares Drop 4% on Significant Q4 Guidance Miss
- S&P 500 on Track for Worst First-Half in 60 Years
- Exclusive-Meta girds for 'fierce' headwinds, slower growth in second half -memo
- Tesla Could Make Billions from Opening Up Its EV Supercharger Network - Goldman
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
May 23, 2022
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
DK- 2880, Bagsvaerd
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
|Form 20-F [X]||Form 40-F [ ]|
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
|Yes [ ]||No [X]|
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 23 May 2022 – On 3 May 2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12-month period beginning 2 February 2022.
Under the programme initiated 3 May 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 4.4 billion in the period from 4 May 2022 to 2 August 2022.
Since the announcement 16 May 2022, the following transactions have been made:
|Accumulated, last announcement||634,689||487,471,914|
|16 May 2022||100,000||742.57||74,256,753|
|17 May 2022||90,000||748.87||67,397,920|
|18 May 2022||100,000||744.81||74,480,694|
|19 May 2022||95,000||729.03||69,257,980|
|20 May 2022||85,000||751.057||63,883,312|
|Accumulated under the programme||1,104,689||836,748,573|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Page 2 of 2
With the transactions stated above, Novo Nordisk owns a total of 13,166,381 B shares of DKK 0.20 as treasury shares, corresponding to 0.6% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12- month period beginning 2 February 2022. As of 20 May 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 11,426,818 B shares at an average share price of DKK 755.99 per B share equal to a transaction value of DKK 8,638,533,594
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 49,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, and YouTube.
|Ambre Brown Morley||+45 3079 9289||[email protected]|
|Natalia Salomao Abrahao (US)||+1 848 304 1027||[email protected]|
|Daniel Muusmann Bohsen||+45 3075 2175||[email protected]|
|Ann Søndermølle Rendbæk||+45 3075 2253||[email protected]|
|David Heiberg Landsted||+45 3077 6915||[email protected]|
|Jacob Martin Wiborg Rode||+45 3075 5956||[email protected]|
|Mark Joseph Root (US)||+1 848 213 3219||[email protected]|
Novo Nordisk A/S
+45 4444 8888
24 25 67 90
|Company announcement No 47 / 2022|
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
|Date: May 23, 2022||
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Reiterates Buy Rating on Novo Nordisk (NOVOB:DC) (NVO)
- Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions
- Sale of undelivered Iveco Group N.V. common shares
Create E-mail Alert Related CategoriesSEC Filings
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!